Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Achieve Life Sciences stock

ACHV
US0044685008
A2QAR3

Price

4.64
Today +/-
-0.06
Today %
-1.48 %
P

Achieve Life Sciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Achieve Life Sciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Achieve Life Sciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Achieve Life Sciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Achieve Life Sciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Achieve Life Sciences Stock Price History

DateAchieve Life Sciences Price
11/4/20244.64 undefined
11/1/20244.71 undefined
10/31/20244.68 undefined
10/30/20244.73 undefined
10/29/20244.72 undefined
10/28/20244.84 undefined
10/25/20244.71 undefined
10/24/20244.69 undefined
10/23/20244.79 undefined
10/22/20244.89 undefined
10/21/20244.98 undefined
10/18/20245.08 undefined
10/17/20245.05 undefined
10/16/20245.00 undefined
10/15/20245.01 undefined
10/14/20244.99 undefined
10/11/20245.00 undefined
10/10/20244.95 undefined
10/9/20245.12 undefined
10/8/20245.27 undefined
10/7/20245.14 undefined

Achieve Life Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Achieve Life Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Achieve Life Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Achieve Life Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Achieve Life Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Achieve Life Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Achieve Life Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Achieve Life Sciences’s growth potential.

Achieve Life Sciences Revenue, EBIT and net profit per share

DateAchieve Life Sciences RevenueAchieve Life Sciences EBITAchieve Life Sciences Net Income
2029e398.3 M undefined280.94 M undefined157.97 M undefined
2028e245.38 M undefined162.39 M undefined109.11 M undefined
2027e126.46 M undefined64.35 M undefined47.99 M undefined
2026e32.56 M undefined-24.29 M undefined-19.26 M undefined
2025e0 undefined-42.26 M undefined-37.08 M undefined
2024e0 undefined-34.77 M undefined-36.43 M undefined
20230 undefined-27.25 M undefined-29.82 M undefined
20220 undefined-40.8 M undefined-42.35 M undefined
20210 undefined-33.09 M undefined-33.15 M undefined
20200 undefined-14.75 M undefined-14.73 M undefined
20190 undefined-16.53 M undefined-16.4 M undefined
20180 undefined-12.81 M undefined-12.69 M undefined
20170 undefined-6.63 M undefined-10.58 M undefined
20165.06 M undefined-18.66 M undefined-20.13 M undefined
201518.16 M undefined-18.75 M undefined-16.8 M undefined
201427.12 M undefined-29.74 M undefined-26.24 M undefined
201329.88 M undefined-35.33 M undefined-31.85 M undefined
201220.1 M undefined-27.65 M undefined-21.1 M undefined
20115.5 M undefined-22.29 M undefined-14.67 M undefined
201013.62 M undefined-10.71 M undefined-12.58 M undefined
200925.54 M undefined1.37 M undefined-5.48 M undefined
20080 undefined-11.11 M undefined-6.18 M undefined
20070 undefined-7.68 M undefined-11.48 M undefined
20060 undefined-11.3 M undefined-14.2 M undefined
20058.25 M undefined-21.81 M undefined-21.1 M undefined
20040 undefined-16.58 M undefined-16.31 M undefined

Achieve Life Sciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0031416185120800080002513520292718500000000032126245398
----66.67300.00300.0012.50-72.22140.00-----------48.00-61.54300.0045.00-6.90-33.33-72.22----------293.7594.4462.45
---33.33-400.00-50.0031.2538.89-100.0041.67-37.50----200.00---20.00-30.77-320.00-95.00-----------------
0-1-1-4-257-55-33-8-7-10-16-7-4-75-4-16-1900000000000000000
0-1-2-6-410-110-70-12-10-16-21-11-7-111-10-22-27-35-29-18-18-6-12-16-14-33-40-27-34-42-2464162280
---66.67-600.00-100.006.25--220.00-------262.50---4.00-76.92-440.00-135.00-120.69-107.41-100.00-360.00----------75.0050.7966.1270.35
0-1-2-8-511-110-20-11-10-16-21-14-11-6-5-12-14-21-31-26-16-20-10-12-16-14-33-42-29-36-37-1947109157
--100.00300.00-37.50-120.00--1,200.00-----9.0960.0031.25-33.33-21.43-45.45-16.67140.0016.6750.0047.62-16.13-38.4625.00-50.0020.0033.33-12.50135.7127.27-30.9524.142.78-48.65-347.37131.9144.04
0000000000000000000000.010.010.010.010.010.020.180.412.728.1210.5919.83000000
---------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Achieve Life Sciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Achieve Life Sciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                             
2.311.6418.2225.1326.5716.9616.88.4615.1216.3319.6620.5849.3258.285.1312.4264.5785.1164.9375.3839.2247.0655.1925.465.2814.616.6635.8543.0224.7715.55
0000000000007.068.040.080.153.111.220.450.718.665.680.010.480.010.010.010000
00000000000000.081.731.09000.360.330.220.110.120.030000000
0000000000000000000000000000000
0.040.270.240.40.640.420.425.350.340.290.150.460.340.450.30.590.722.991.213.765.772.921.990.950.610.930.661.121.422.451.33
2.351.9118.4625.5327.2117.3817.2213.8115.4616.6219.8121.0456.7266.857.2414.2568.489.3266.9580.1853.8755.7757.3126.925.915.5417.3336.9744.4427.2216.87
0.911.191.121.171.731.440.860.50.41.311.611.481.011.190.10.040.070.090.180.370.40.260.60.260.060.040.390.190.080.130.08
0000000000000000000000000000000
0000000000000000000000000000000
0000000000000000000000002.532.312.091.861.641.421.2
0000000000000000000000001.031.031.031.031.031.031.03
0.160.090.060.070000000.050.050.190.460.010.50.510.510.891.471.430.270.310.290.360.170.240.240.170.060.08
1.071.281.181.241.731.440.860.50.41.311.661.531.21.650.110.540.580.61.071.841.830.530.910.553.983.553.753.322.922.642.39
3.423.1919.6426.7728.9418.8218.0814.3115.8617.9321.4722.5757.9268.57.3514.7968.9889.9268.0282.0255.756.358.2227.479.8819.0921.0840.2947.3629.8619.26
                                                             
3.014.1430.1134.2834.8635.0137.1438.0843.356.0170.0986.2123.44154.7837.770.010.010.010.010.020.020.020.030.030.010.020.040.080.080.090.09
0000000-0.350000000.5756.0773.8107.58108.99165.4168.24191.37211.59213.2420.5641.1663.7197.64121.55144.15164.21
-4.24-13.13-19.07-17.36-16.34-27.51-27.07-29.22-28.68-40.31-50.78-67.09-88.19-111.74-41.83-48.01-53.49-66.07-80.74-101.84-133.69-159.96-176.81-196.94-12.69-25.38-45.7-60.43-93.59-135.94-165.75
0-0.05-0.09-0.04-0.02-0.01-0.0200.040.030-0.040.0102.642.642.642.612.642.642.642.622.632.640.01000000
0000000000000000000000000000000
-1.23-9.0410.9516.8818.57.4910.058.5114.6615.7319.3119.0735.2643.04-0.8510.7122.9644.1330.966.2237.2134.0537.4418.977.8915.818.0537.2928.048.3-1.45
0.460.771.462.22.612.952.830.81.21.80.20.821.262.371.052.2514.450.893.221.330.140.071.342.120.210.140.860.330.841.660.62
00.831.571.211.741.230.220001.222.134.4111.93000005.7213.4915.6611.876.051.773.132.012.63.713.873.01
04010000000.230.235.555.6001025.2726.153.420.216.257.40.230000000.53
0.52.935555550000004.670000000000000000
0.20.310.210.230.150.090000.140.150.080.030.0200.631.331.311.421.081.090.240.050.060.03000016.0716.66
1.168.848.249.649.59.278.055.81.21.941.83.2611.2519.925.722.8825.7827.4730.7911.5514.9322.2220.668.462.013.272.872.934.5521.620.81
3.483.410.470.240.942.050000.270.120.040.02001.23.716.76.344.253.540.010.110.05000014.9200
0000000000000000000000000000000
00000000000.240.211.395.542.49016.5311.6200000000.010.160.0800.070.01
3.483.410.470.240.942.050000.270.360.2411.415.542.491.220.2418.326.344.253.540.010.110.0500.010.160.0814.920.070.01
4.6412.258.719.8810.4411.328.055.81.22.212.163.522.6625.468.214.0846.0245.7937.1315.818.4722.2320.778.512.013.283.033.0119.4721.6720.82
3.413.2119.6626.7628.9418.8118.114.3115.8617.9421.4722.5757.9268.57.3614.7968.9889.9268.0382.0255.6856.2858.2127.489.919.0821.0840.347.5129.9719.37
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Achieve Life Sciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Achieve Life Sciences's financial health and stability.

Assets

Achieve Life Sciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Achieve Life Sciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Achieve Life Sciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Achieve Life Sciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (k)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-1,000-2,000-8,000-5,0001,0001,000-11,0000-2,0000-11,000-10,000-16,000-21,000-11,000-8,000-4,000-5,000-12,000-14,000-21,000-31,000-26,000-16,000-20,000-10,000-12,000-16,000-14,000-33,000-42,000-29,000
00000000000000000000000000000000
0000000000000000000000000-3000000
005-2100-1-200011200-439-190-18-3117-10-3000100
0000000000000000-306-5-120207122475
00000000000000000000000000000000
00000000000000000000000000000000
-1-2-3-731-100-31-10-9-14-8-10-7-1234-26-20-43-35-17-9-29-9-10-15-13-29-37-24
00000-100000000000000000000000000
-1-10-11-5-4904-8-2-2-220116152-5925-21325-21012-550000
-1-10-10-5-3904-7-1-2-220116152-5925-20325-11012-550000
00000000000000000000000000000000
032200100-500000400000000000001400
20122400005121416370001747054022000144421015
233243110051213153704017470540251702191732361915
000000000500000000000021701412270190
00000000000000000000000000000000
00051-1000-101-14802254-384-10-3136-19547197-18-9
-2.16-2.68-4.21-8.072.950.23-10.84-0.16-4.011.06-11.31-10.6-15.05-8.48-10.64-7.9-12.3134.86-26.91-20.34-43.78-36.18-17.39-9.47-29.73-9.11-10.67-15.27-13.49-29.44-37.55-24.5
00000000000000000000000000000000

Achieve Life Sciences stock margins

The Achieve Life Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Achieve Life Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Achieve Life Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Achieve Life Sciences's sales revenue. A higher gross margin percentage indicates that the Achieve Life Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Achieve Life Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Achieve Life Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Achieve Life Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Achieve Life Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Achieve Life Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Achieve Life Sciences Margin History

Achieve Life Sciences Gross marginAchieve Life Sciences Profit marginAchieve Life Sciences EBIT marginAchieve Life Sciences Profit margin
2029e-98.76 %70.53 %39.66 %
2028e-98.76 %66.18 %44.47 %
2027e-98.76 %50.89 %37.95 %
2026e-98.76 %-74.61 %-59.17 %
2025e-98.76 %0 %0 %
2024e-98.76 %0 %0 %
2023-98.76 %0 %0 %
2022-98.76 %0 %0 %
2021-98.76 %0 %0 %
2020-98.76 %0 %0 %
2019-98.76 %0 %0 %
2018-98.76 %0 %0 %
2017-98.76 %0 %0 %
2016-98.76 %-368.77 %-397.83 %
2015-98.76 %-103.25 %-92.51 %
2014-98.76 %-109.66 %-96.76 %
2013-98.76 %-118.24 %-106.59 %
2012-98.76 %-137.56 %-104.98 %
2011-292 %-405.27 %-266.73 %
2010-35.76 %-78.63 %-92.36 %
200920.87 %5.36 %-21.46 %
2008-98.76 %0 %0 %
2007-98.76 %0 %0 %
2006-98.76 %0 %0 %
2005-196.85 %-264.36 %-255.76 %
2004-98.76 %0 %0 %

Achieve Life Sciences Stock Sales Revenue, EBIT, Earnings per Share

The Achieve Life Sciences earnings per share therefore indicates how much revenue Achieve Life Sciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Achieve Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Achieve Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Achieve Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Achieve Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Achieve Life Sciences Revenue, EBIT and net profit per share

DateAchieve Life Sciences Sales per ShareAchieve Life Sciences EBIT per shareAchieve Life Sciences Earnings per Share
2029e11.6 undefined0 undefined4.6 undefined
2028e7.15 undefined0 undefined3.18 undefined
2027e3.68 undefined0 undefined1.4 undefined
2026e0.95 undefined0 undefined-0.56 undefined
2025e0 undefined0 undefined-1.08 undefined
2024e0 undefined0 undefined-1.06 undefined
20230 undefined-1.37 undefined-1.5 undefined
20220 undefined-3.85 undefined-4 undefined
20210 undefined-4.08 undefined-4.08 undefined
20200 undefined-5.42 undefined-5.42 undefined
20190 undefined-40.32 undefined-40 undefined
20180 undefined-71.17 undefined-70.5 undefined
20170 undefined-331.5 undefined-529 undefined
2016506 undefined-1,866 undefined-2,013 undefined
20151,816 undefined-1,875 undefined-1,680 undefined
20142,712 undefined-2,974 undefined-2,624 undefined
20132,988 undefined-3,533 undefined-3,185 undefined
20122,010 undefined-2,765 undefined-2,110 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined

Achieve Life Sciences business model

Achieve Life Sciences Inc is a biopharmaceutical company specializing in researching and developing novel treatment options for tobacco addiction. The company was founded in 1991 and is headquartered in Seattle, Washington. Answer: Achieve Life Sciences Inc focuses on researching and developing innovative therapies for treating tobacco addiction. Achieve Life Sciences is one of the most popular companies on Eulerpool.com.

Achieve Life Sciences SWOT Analysis

Strengths

Achieve Life Sciences Inc benefits from a strong foundation in advanced research and development. This enables the company to innovate and develop cutting-edge products and solutions in the life sciences industry. Their commitment to investing in R&D gives them a competitive advantage and positions them as a leader in their field.

The company is led by a well-experienced management team with extensive knowledge and expertise in the life sciences sector. Their collective experience allows for effective decision-making and strategic planning, ensuring the company remains on a growth trajectory. The team's strong leadership skills contribute to Achieve Life Sciences Inc's overall success and performance.

Weaknesses

Achieve Life Sciences Inc currently has a limited product portfolio, with a focus on a specific segment of the market. This narrow product range may limit their revenue potential and leave them vulnerable to shifts in market demand. Diversification of their product offerings could help mitigate this weakness and increase their market share.

The company heavily relies on external funding sources, such as investments and grants, to support its operations and research activities. This dependency on external funding exposes Achieve Life Sciences Inc to potential risks and uncertainties in securing sufficient financial resources. Developing alternative sources of funding and establishing strategic partnerships could reduce this weakness and enhance financial stability.

Opportunities

The global market for life sciences is experiencing significant growth, driven by increasing healthcare needs and advancements in technology. This presents an opportunity for Achieve Life Sciences Inc to expand its market presence and tap into new geographical regions. By capitalizing on this trend, the company can reach a larger customer base and achieve higher revenue growth.

The rapid advancements in technology and emerging innovations within the life sciences sector provide immense opportunities for Achieve Life Sciences Inc. By staying at the forefront of these developments, the company can leverage new technologies to enhance their existing products or create novel solutions, gaining a competitive edge in the market.

Threats

Achieve Life Sciences Inc faces intense competition from well-established players within the life sciences industry. These competitors often have greater financial resources and broader product portfolios, posing a threat to the company's market share and growth potential. To mitigate this threat, Achieve Life Sciences Inc must emphasize their unique value proposition, continue to innovate, and strengthen customer relationships.

The life sciences industry is heavily regulated, and compliance with various regulations and standards can pose challenges to Achieve Life Sciences Inc. Changes in regulatory requirements or failure to comply with existing regulations can lead to legal issues, product recalls, and reputational damage. To address this threat, the company must maintain strict compliance measures, invest in regulatory expertise, and stay updated with any changes in the regulatory landscape.

Achieve Life Sciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Achieve Life Sciences historical P/E ratio, EBIT multiple, and P/S ratio

Achieve Life Sciences shares outstanding

The number of shares was Achieve Life Sciences in 2023 — This indicates how many shares 19.827 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Achieve Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Achieve Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Achieve Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Achieve Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Achieve Life Sciences stock splits

In Achieve Life Sciences's history, there have been no stock splits.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Achieve Life Sciences.

Achieve Life Sciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.24 -0.25  (-5.8 %)2024 Q2
3/31/2024-0.25 -0.26  (-4.46 %)2024 Q1
12/31/2023-0.32 -0.26  (18.9 %)2023 Q4
9/30/2023-0.39 -0.34  (11.94 %)2023 Q3
6/30/2023-0.43 -0.43  (-0.02 %)2023 Q2
3/31/2023-0.7 -0.5  (28.54 %)2023 Q1
12/31/2022-0.85 -0.83  (1.96 %)2022 Q4
9/30/2022-1.15 -1.35  (-17.42 %)2022 Q3
6/30/2022-0.85 -1.08  (-27 %)2022 Q2
3/31/2022-0.83 -0.8  (3.41 %)2022 Q1
1
2
3
4
5
...
9

Achieve Life Sciences shareholders

%
Name
Stocks
Change
Date
17.62485 % Franklin Advisers, Inc.6,052,37488,2866/30/2024
10.17236 % B. Riley Asset Management, LLC3,493,190-8104/10/2024
7.14354 % Propel Bio Management, LLC2,453,09206/30/2024
5.18684 % BlackRock Institutional Trust Company, N.A.1,781,1621,728,7316/30/2024
4.49598 % Contrarian Alpha Management, L.L.C.1,543,918105,0005/15/2024
4.45047 % Patrick (Callahan J. III)1,528,2931,528,29311/9/2023
4.38477 % The Vanguard Group, Inc.1,505,731557,2906/30/2024
4.04302 % Sofinnova Investments, Inc1,388,372-129,8586/30/2024
2.04029 % Geode Capital Management, L.L.C.700,635493,8516/30/2024
1.90448 % Nantahala Capital Management, LLC654,00006/30/2024
1
2
3
4
5
...
10

Achieve Life Sciences Executives and Management Board

Mr. John Bencich(46)
Achieve Life Sciences Chief Executive Officer, Director (since 2014)
Compensation 1.5 M
Mr. Richard Stewart(64)
Achieve Life Sciences Executive Chairman of the Board (since 2017)
Compensation 1.27 M
Dr. Cindy Jacobs(65)
Achieve Life Sciences President, Director, Chief Medical Officer (since 2008)
Compensation 1.12 M
Dr. Bridget Martell(57)
Achieve Life Sciences Independent Director
Compensation 81,858
Mr. Vaughn Himes(62)
Achieve Life Sciences Independent Director
Compensation 74,221
1
2

Most common questions regarding Achieve Life Sciences

What values and corporate philosophy does Achieve Life Sciences represent?

Achieve Life Sciences Inc represents a set of core values and a corporate philosophy that guide its operations and decision-making. The company is committed to improving the lives of patients by developing and commercializing innovative therapies for potential life-threatening diseases. Achieve Life Sciences emphasizes collaboration, integrity, and excellence in all aspects of its business. Through its dedication to scientific advancements and a patient-centric approach, Achieve Life Sciences actively contributes to the healthcare industry and strives to make a meaningful impact on the well-being of individuals. With its focus on delivering transformative treatments, Achieve Life Sciences Inc stands as a leader in the field.

In which countries and regions is Achieve Life Sciences primarily present?

Achieve Life Sciences Inc is primarily present and operates in the United States.

What significant milestones has the company Achieve Life Sciences achieved?

Achieve Life Sciences Inc has achieved several significant milestones. It successfully completed a Phase 1 clinical study evaluating the safety and pharmacokinetics of their novel smoking cessation therapy known as cytisine. The company also carried out a Phase 2b clinical trial, demonstrating the efficacy, safety, and tolerability of cytisine in helping smokers quit. Achieve Life Sciences Inc further obtained breakthrough therapy designation from the FDA for cytisine, recognizing its potential to address unmet medical needs. These achievements highlight the company's dedication to advancing innovative solutions for smoking cessation and its commitment to providing effective treatments for smokers aiming to improve their health and well-being.

What is the history and background of the company Achieve Life Sciences?

Achieve Life Sciences Inc is a pharmaceutical company specializing in the development and commercialization of smoking cessation and nicotine addiction therapies. Founded in 2015, Achieve Life Sciences is dedicated to improving the lives of individuals struggling with nicotine dependency. The company has a strong focus on leveraging innovative technologies and scientific research to provide effective treatment options. Achieve Life Sciences strives to address the global public health epidemic caused by tobacco addiction through the development of novel therapies. With a dedicated team and a commitment to improving public health, Achieve Life Sciences Inc is at the forefront of combating nicotine addiction.

Who are the main competitors of Achieve Life Sciences in the market?

Achieve Life Sciences Inc faces competition from several companies in the market. Some of its main competitors include Chantix, manufactured by Pfizer, and Zyban, manufactured by GlaxoSmithKline. These companies also produce smoking cessation products targeted towards helping individuals quit smoking.

In which industries is Achieve Life Sciences primarily active?

Achieve Life Sciences Inc is primarily active in the pharmaceutical industry.

What is the business model of Achieve Life Sciences?

Achieve Life Sciences Inc's business model is focused on developing and commercializing innovative therapies to help people quit smoking. The company is dedicated to providing effective solutions for nicotine addiction and smoking cessation through its proprietary product, Cytisine. Achieve Life Sciences aims to address the global public health issue of tobacco dependence and offer a safer alternative to traditional smoking cessation methods. With ongoing research and development efforts in this field, Achieve Life Sciences Inc strives to improve the lives of individuals struggling with nicotine addiction worldwide.

What is the P/E ratio of Achieve Life Sciences 2024?

The Achieve Life Sciences P/E ratio is -2.53.

What is the P/S ratio of Achieve Life Sciences 2024?

The Achieve Life Sciences P/S ratio is 0.

What is the Quality Investing of Achieve Life Sciences?

The Quality Investing for Achieve Life Sciences is 4/10.

What is the revenue of Achieve Life Sciences 2024?

The revenue cannot currently be calculated for Achieve Life Sciences.

How high is the profit of Achieve Life Sciences 2024?

The expected Achieve Life Sciences profit is -36.43 M USD.

What is the business model of Achieve Life Sciences

Achieve Life Sciences Inc is an innovative company specialized in researching, developing, and marketing therapies for smoking cessation. Their business model includes various aspects that cater to the needs of individuals who want to quit smoking. One of the main focuses of Achieve Life Sciences Inc is the research and development of medications for smoking cessation. The company concentrates on creating nicotine replacement therapies that help smokers overcome their nicotine addiction without suffering. This includes Nicotine Replacement Therapies (NRT) and medications based on Varenicline. Another area of focus for the company is the development of innovative technologies to support smokers in quitting. This includes applications and other digital platforms that assist smokers in changing their behaviors and extending their abstinence. Additionally, the company explores new treatment methods that offer alternative approaches to nicotine substitution. A significant part of Achieve Life Sciences Inc's business model involves collaborating with various companies and institutions to promote the marketing and distribution of nicotine replacement therapies and other smoking cessation medications. The company works with national and international partners to offer a wide range of products and services. The business model of Achieve Life Sciences Inc is complemented by a strong customer orientation, evident in their high level of service and quality management. Customer satisfaction is always a priority for the company, which is why they constantly review and optimize their products and services to best meet the needs of smokers. Overall, the business model of Achieve Life Sciences Inc is geared towards addressing the needs of individuals who want to quit smoking. The company relies on a diverse range of products and services made possible through research and development, innovative technologies, and collaboration with various partners and institutions. With a focus on customer orientation and quality management, the company ensures that their products and services adhere to the highest standards and help smokers overcome their nicotine addiction.

What is the Achieve Life Sciences dividend?

Achieve Life Sciences pays a dividend of 0 USD distributed over payouts per year.

How often does Achieve Life Sciences pay dividends?

The dividend cannot currently be calculated for Achieve Life Sciences or the company does not pay out a dividend.

What is the Achieve Life Sciences ISIN?

The ISIN of Achieve Life Sciences is US0044685008.

What is the Achieve Life Sciences WKN?

The WKN of Achieve Life Sciences is A2QAR3.

What is the Achieve Life Sciences ticker?

The ticker of Achieve Life Sciences is ACHV.

How much dividend does Achieve Life Sciences pay?

Over the past 12 months, Achieve Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Achieve Life Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Achieve Life Sciences?

The current dividend yield of Achieve Life Sciences is .

When does Achieve Life Sciences pay dividends?

Achieve Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Achieve Life Sciences?

Achieve Life Sciences paid dividends every year for the past 0 years.

What is the dividend of Achieve Life Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Achieve Life Sciences located?

Achieve Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Achieve Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Achieve Life Sciences from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Achieve Life Sciences pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Achieve Life Sciences in the year 2023?

In the year 2023, Achieve Life Sciences distributed 0 USD as dividends.

In which currency does Achieve Life Sciences pay out the dividend?

The dividends of Achieve Life Sciences are distributed in USD.

All fundamentals about Achieve Life Sciences

Our stock analysis for Achieve Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Achieve Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.